In 2025, the Psychiatric University Hospital Zurich (PUK) launched the scientifically based prevention programme “ProMental with the support of Schwabe Pharma AG. The aim of the pilot project is to identify personal risk factors for dementia at an early stage in people with mild cognitive impairment and to reduce these through targeted measures, as there are currently no effective treatments for dementia.
As part of the six-month program, participants receive individual recommendations for a preventive lifestyle designed to slow the progression of cognitive impairment. The program includes at least two weekly group activities in the areas of exercise, healthy eating, and cognitive training.
There is a great need for action: according to the organization Alzheimer Switzerland, there are over 33,000 new cases each year in Switzerland. This places a heavy burden on both those affected and their families. If the pilot project proves successful, it will be rolled out nationwide in 2026.
Life Science Communication is supporting Schwabe Pharma AG with communication measures at various levels for the launch of the ProMental programme.
